Marshall Wace, LLP Rocket Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 19,583 shares of RCKT stock, worth $361,502. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,583Holding current value
$361,502% of portfolio
0.0%Shares
13 transactions
Others Institutions Holding RCKT
# of Institutions
194Shares Held
91.9MCall Options Held
222KPut Options Held
111K-
Rtw Investments, LP New York, NY17.7MShares$327 Million6.36% of portfolio
-
Wellington Management Group LLP Boston, MA9.16MShares$169 Million0.04% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$114 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.81MShares$107 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.33MShares$79.9 Million0.47% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $1.4B
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...